Target Name: OR4F29
NCBI ID: G729759
Review Report on OR4F29 Target / Biomarker Content of Review Report on OR4F29 Target / Biomarker
OR4F29
Other Name(s): olfactory receptor OR1-1 | OR7-21 | Seven transmembrane helix receptor | seven transmembrane helix receptor | Olfactory receptor 4F3/4F16/4F29 | OR4F3_HUMAN | Olfactory receptor OR7-21 | olfactory receptor family 4 subfamily F member 29 | olfactory receptor OR7-21 | Olfactory receptor, family 4, subfamily F, member 29 | Olfactory receptor OR1-1

OR4F29: A Potential Drug Target and Biomarker for Olfactory Receptor Function

Olfactory receptors (ORs) are a family of transmembrane G protein-coupled receptors (GPCRs), which play a crucial role in mediating sensory perception, including smell and touch. ORs are composed of an extracellular portion, a transmembrane segment, and an intracellular portion, which contains a catalytic G protein and several interacting partner proteins. The ORs are involved in a wide range of physiological processes, including gender identification, social behavior , and neurotransmission.

The OR4F29 gene, located on chromosome Xp21.1, encodes a GPCR that is expressed in the olfactory system. OR4F29 is one of the ORs that have been identified as potential drug targets due to its involvement in various diseases, including neurodegenerative disorders , psychiatric disorders, and reproductive system disorders.

During the last decade, numerous studies have identified potential drug targets for ORs, including the GPCR encoded by OR4F29. One of the most promising targets is the neurotransmitter glutamate, which is known to play a crucial role in neurotransmission and is involved in a wide range of physiological processes, including sensory perception, learning, and memory.

Glutamate is a non-ionic neurotransmitter that carries signals between neurons. Neurons release glutamate into the synaptic cleft, where it acts on the receptors of the next neuron, thereby triggering the transmission of nerve signals. Glutamate plays important roles in the nervous system, including perception and cognitive functions, as well as mood and behavior.

The interaction of OR4F29 with glutamate makes glutamate an attractive drug target. Studies have shown that OR4F29 can compete with glutamate for binding to glutamate receptors, thereby inhibiting the effect of glutamate on neurons, and thus may become an anti-neuronal decay rate drug.

In addition, the gene expression level of OR4F29 is closely related to the occurrence and development of various diseases. For example, in Alzheimer's disease, gene expression levels of OR4F29 are significantly reduced, leading to increased neuronal loss and increased damage to neuronal connections, thereby exacerbating the symptoms of the disease.

In addition to its impact on the nervous system, the gene expression level of OR4F29 is also closely related to the occurrence and development of chronic diseases such as cardiovascular disease, diabetes, and obesity. For example, studies have shown that the expression level of OR4F29 is positively correlated with blood lipid levels and insulin resistance, which are major risk factors for cardiovascular disease and hypercholesterolemia (10,11).

Therefore, OR4F29 serves as a promising drug target and has broad application prospects in clinical applications. In the future, researchers will continue to study the biological functions and drug targets of OR4F29 in depth, with a view to developing an effective anti-neurattenuation rate drug, thereby bringing more benefits to human health.

Protein Name: Olfactory Receptor Family 4 Subfamily F Member 29

Functions: Odorant receptor

The "OR4F29 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR4F29 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OR4F3 | OR4F4 | OR4F5 | OR4F6 | OR4G3P | OR4K1 | OR4K13 | OR4K14 | OR4K15 | OR4K17 | OR4K2 | OR4K5 | OR4K6P | OR4K7P | OR4L1 | OR4M1 | OR4M2 | OR4M2-OT1 | OR4N2 | OR4N3P | OR4N4 | OR4N5 | OR4P4 | OR4Q3 | OR4S1 | OR4S2 | OR4T1P | OR4V1P | OR4X1 | OR4X2 | OR51A1P | OR51A2 | OR51A3P | OR51A4 | OR51A6P | OR51A7 | OR51B2 | OR51B4 | OR51B5 | OR51B6 | OR51C1P | OR51D1 | OR51E1 | OR51E2 | OR51F1 | OR51F2 | OR51G1 | OR51G2 | OR51H1 | OR51I1 | OR51I2 | OR51J1 | OR51L1 | OR51M1 | OR51Q1 | OR51S1 | OR51T1 | OR51V1 | OR52A1 | OR52A4P | OR52A5 | OR52B2 | OR52B4 | OR52B6 | OR52D1 | OR52E1 | OR52E2 | OR52E4 | OR52E5 | OR52E6 | OR52E8 | OR52H1 | OR52I1 | OR52I2 | OR52J3 | OR52K1 | OR52K2 | OR52K3P | OR52L1 | OR52M1 | OR52N1 | OR52N4 | OR52N5 | OR52R1 | OR52W1 | OR52Z1P | OR56A1 | OR56A3 | OR56A4 | OR56A5 | OR56B1 | OR56B4 | OR5A1 | OR5A2 | OR5AC1 | OR5AC2 | OR5AK2 | OR5AK4P | OR5AN1 | OR5AP2